Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06308081 · ClinicalTrials.gov registry record · NA
Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 1,155
- Enrollment target
NCT06308081: Completed NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06308081 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,155 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06308081, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,155 participants
- Enrollment target
Study Summary
The investigators long-term goal is to reduce tobacco use and tobacco-related health disparities among SGM populations. The objective of Project SMART (Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens) is to evaluate the effectiveness of an sexual gender minority (SGM) -tailored social media intervention to prevent vaping initiation among SGM youth ages 13-20 years. The investigators central hypothesis is that SGM-tailored anti-vaping social media messages will be more effective than existing non-tailored messages to prevent vaping initiation among SGM youth. The scientific premise for this work is based on principles of cultural tailoring in health communication for vulnerable populations, the Health Equity Promotion Model, and the Message Impact Framework. The investigators are developing and evaluating a social media intervention because SGM youth have a high rate of social media use and are more likely to go online for health information than non-SGM youth. Social media, moreover, are increasingly used for health promotion to address health disparities and well-being of SGM populations. The investigators will conduct rapid-cycle feedback with stakeholders including SGM organization leaders to provide input on the message design, testing, and intervention implementation to ensure feasibility and acceptability of the intervention.
Primary Outcome
We will measure susceptibility to vaping using four items previously used on PATH Wave 7 youth questionnaire and NYTS 2022 Questionnaire: 1. Have you ever been curious about using an e-cigarette or other electronic nicotine products? (1 = Not at all curious; 2 = A little curious; 3 = Somewhat curious; 4 = Very curious) 2. Do you think you will use an e-cigarette or an electronic nicotine product in the next year? (1 = Definitely not; 2 = Probably not; 3 = Probably yes; 4 = Definitely yes) 3. Do
Interventions
- OTHER Tailored
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,155 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2025-08-15 |
| Phase | NA |
What the finished NCT06308081 record still lists
NCT06308081 is an interventional study that assigns participants to a tested intervention. Its 1,155 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (18% lower).
The record links to 0 conditions, and to 1 intervention - of which Tailored is the first listed.
NCT06308081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06308081 about?
NCT06308081 is a clinical study titled "Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens". The investigators long-term goal is to reduce tobacco use and tobacco-related health disparities among SGM populations. The objective of Project SMART (Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens) is to evaluate the effectiveness of an sexual gender mi...
What is the current status of trial NCT06308081?
This trial is currently completed. It is a NA study. The enrollment target is 1,155 participants. The study started on 2024-02-21. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT06308081?
The interventions under investigation include: Tailored (OTHER).
Who is sponsoring clinical trial NCT06308081?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06308081's enrollment target sits among peer trials
1,155 92nd of 2000 higher than 1,909 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI